BioNexus Gene Lab Corp (BGLC): Nasdaq/NYSE listing notice — BioNexus Gene Lab receives Nasdaq bid-price deficiency notice

BioNexus Gene Lab Corp

Closing bid price below $1.00 for 33 consecutive business days (Sept 20 - Nov 3, 2023).
180-day compliance period ends May 6, 2024; cure requires $1.00 close for 10 straight days.
Company may be eligible for an additional 180-day cure period if it meets other listing standards.
Failure to cure could result in delisting from Nasdaq Capital Market.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

BioNexus Gene Lab Corp received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2), 5810(c)(3)(A)

Exact text from the filing

November 6, 2023, BioNexus Gene Lab Corp. (the “Company”) received a letter from the Listing Qualifications Department of the Nasdaq Stock Market (“Nasdaq”) regarding the Company’s failure to comply with Nasdaq Continued Listing Rule (“Rule”) 5550(a)(2), which requires listed securities to maintain a minimum bid price of $1.00 per share. A failure to comply with Rule 5550(a)(2) exists when listed securities fail to maintain a closing bid price of at least $1.00 per share for 30 consecutive business days. Based on the closing bid price for the last 33 consecutive business days (including, in pa

View on SEC.gov

20 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

BioNexus Gene Lab Corp filing history →

Source: SEC EDGAR

accession 0001477932-23-008275

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.